Description:
This study is designed to assess the safety and clinical activity of tamoxifen and the COX
inhibitor, aspirin, given in combination with standard AC-T chemotherapy (doxorubicin,
cyclophosphamide, and paclitaxel) for the treatment of high-risk estrogen receptor (ER)+,
human epidermal growth factor receptor 2 (HER2)- breast cancer. If successful, the study
could improve long-term outcomes for a subpopulation of women with aggressive stage I-III
ER+/HER2- breast cancer.
Title
- Brief Title: COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
- Official Title: COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Therapy for Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Stage I-III Breast Cancer
Clinical Trial IDs
- ORG STUDY ID:
21822
- NCT ID:
NCT04038489
Conditions
- Breast Cancer
- Estrogen Receptor-positive Breast Cancer
Interventions
Drug | Synonyms | Arms |
---|
Aspirin | | Tamoxifen and Aspirin with AC-T Chemotherapy |
Tamoxifen Pill | | Tamoxifen and Aspirin with AC-T Chemotherapy |
Doxorubicin | Adriamycin | Tamoxifen and Aspirin with AC-T Chemotherapy |
Cyclophosphamide | Cytoxan | Tamoxifen and Aspirin with AC-T Chemotherapy |
Paclitaxel | Taxol | Tamoxifen and Aspirin with AC-T Chemotherapy |
Purpose
This study is designed to assess the safety and clinical activity of tamoxifen and the COX
inhibitor, aspirin, given in combination with standard AC-T chemotherapy (doxorubicin,
cyclophosphamide, and paclitaxel) for the treatment of high-risk estrogen receptor (ER)+,
human epidermal growth factor receptor 2 (HER2)- breast cancer. If successful, the study
could improve long-term outcomes for a subpopulation of women with aggressive stage I-III
ER+/HER2- breast cancer.
Trial Arms
Name | Type | Description | Interventions |
---|
Tamoxifen and Aspirin with AC-T Chemotherapy | Experimental | AC-T chemotherapy includes 4 cycles of doxorubicin and cyclophosphamide given every 2 or 3 weeks followed by either 12 weekly cycles of lower dose paclitaxel or 4 cycles of higher dose paclitaxel every 2 or 3 weeks. During this time, all participants would receive daily aspirin and daily tamoxifen. After the AC-T chemotherapy, participants will undergo standard of care surgery to remove any remaining tumor. | - Aspirin
- Tamoxifen Pill
- Doxorubicin
- Cyclophosphamide
- Paclitaxel
|
Eligibility Criteria
Inclusion Criteria:
1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the
duration of the study
3. Male or female, aged 18 or older
4. Newly diagnosed with ER+/HER2- stage I-III breast cancer according to American Society
of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines and the
8th edition of the American Joint Committee on Cancer (AJCC); ER positive is defined
as ≥ 1% positive nuclear staining
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
6. Life expectancy ≥ 6 months
7. Women of childbearing potential and men must agree to use adequate contraception (see
section 5.4) prior to study entry and for at least 3 months following the last dose of
tamoxifen
8. If genomic profiling has been performed (OncotypeDx, Mammaprint or other), then the
score must be in a medium- or high-risk range.
9. Adequate Organ Function as described below. There are no requirements regarding recent
transfusions Absolute Neutrophil Count ≥1000/mm3 Platelets ≥100,000/mm3 Hemoglobin ≥9
g/dL Serum Creatinine or Glomerular Filtration Rate (GFR) ≤ 1.5 x upper limit of
normal (ULN) Bilirubin ≤ 1.5 x ULN (except in patients with Gilbert's disease, where
bilirubin to 4x ULN or direct bilirubin ≤ ULN is allowed) Aspartate aminotransferase
(AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN
10. Ability to take oral medication
Exclusion Criteria:
1. Receipt of any systemic treatment for the current diagnosis of breast cancer (breast
biopsy, excisional biopsy, or other local therapy is acceptable as long as residual
disease is present and is appropriate for systemic chemotherapy and additional
curative intent resection)
2. Current use of anticoagulant (e.g. warfarin (Coumadin), heparin, direct oral
anticoagulants (DOAC)) within 72 hours of registration
3. Pregnancy or lactation
4. Currently in prison
5. Requirement for supplemental oxygen therapy
6. Current active cancer other than breast cancer
7. History of severe bleeding that, in the treating investigator's opinion, would put the
patient at increased risk with daily 325 mg aspirin use
8. Known allergic reactions to aspirin, tamoxifen, doxorubicin, cyclophosphamide, or
paclitaxel
9. Participants classified according to the New York Heart Association classification as
having Class II - IV heart disease (section 12.2)
10. History of thrombosis or cerebrovascular accident
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Pathologic complete response (pCR) rate |
Time Frame: | At the time of surgery, following completion of AC-T chemotherapy, usually about 7.5 months |
Safety Issue: | |
Description: | Rate of participants that no longer have any tumor identified at the time of surgery after chemotherapy |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | University of Virginia |
Trial Keywords
Last Updated
August 12, 2021